SEC Legend-Regulation D Offerings

Memoranda regarding the offerings for Know Labs, Inc. described in this email will be filed with the Securities and Exchange Commission(“SEC”). These offerings may only be purchased by accredited investors as defined in Rule 501(a) of Regulation D of the Securities Act of 1933, as amended. The SEC typically will not review, and will not qualify, those memoranda. The SEC does not approve, pass upon the merits, or pass upon the accuracy or completeness of the information in such memoranda. If you are an accredited investor, you may obtain a copy of the memoranda for Know Labs, Inc here.

Liquidity Risk-Regulation D Offerings

Investment in Know Labs, Inc. have a high degree of risk including the lack of a market for their securities, as well as other risks common to Regulation D investments generally, including, but not limited to, other substantial restrictions on transferability, making this investment highly illiquid. Know Labs, Inc. can make no assurances about the success of their products, licensing or marketing efforts, any plans to make their securities liquid at any time, if  ever, or their ability to eventually qualify for a listing on a national, or any other, securities exchange; consequently, investors in Know Labs, Inc. may lose some or all of their investments.

Forward-Looking Statements

We make statements herein that are considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as  amended (the “Securities Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,”  “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend for these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement herein for purposes of complying with those safe harbor provisions. Similar statements are made in the Offering Circulars or offering memoranda of the companies mentioned herein. These forward-looking statements reflect, as applicable, our or mentioned companies’ current views about plans, intentions, expectations, strategies and prospects, which are based on the information currently available to they or us and on assumptions they or we have made. Although they or we believe that such plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, they or we can give no assurance that such plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond their or our control. For further discussion of the factors that could affect outcomes, please refer to the risk factors set forth in the “Risk Factors” sections of the Final Offering Circular of Regulation A+ Offerings or the memoranda of the Regulation D Offerings. They or we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

This Presentation (the “Presentation”) contains sensitive business and financial information. It is being delivered on behalf of the Company by Boustead Securities LLC (“BSL”). The sole purpose of this Presentation is to assist the recipient in deciding whether to proceed with a further inquiry of the Company. This Presentation does not purport to be all-inclusive or to necessarily contain all the information that a prospective investor may desire in evaluating a possible business transaction with the Company.

By accepting this Presentation, the recipient agrees to keep confidential the information contained herein or made available in connection with any further inquiry of the Company. This Presentation may not be photocopied, reproduced or distributed to others at any time without the prior written consent of BSL. Upon request, the recipient will promptly return all materials received from the Company or BSL (including this Presentation) without retaining any copies thereof, all in accordance with the Confidentiality Agreement.

This Presentation has been prepared for informational purposes relating to this transaction only and upon the express understanding that it will be used only for the purposes set forth above. Neither the Company nor BSL makes any express or implied representation or warranty as to the accuracy or completeness of the information contained herein or made available in connection with any further investigation of the Company. Each of the Company and BSL expressly disclaims any and all liability which may be based on such information, errors therein or omissions there from. The recipient shall be entitled to rely solely on the representations and warranties made to it in any definitive agreement and the due diligence that recipient conducts.

In furnishing this Presentation, neither the Company nor BSL undertakes any obligation to provide the recipient with access to any additional information. This Presentation shall neither be deemed an indication of the state of affairs of the Company nor constitute an indication that there has not  been any change in the Company or affairs of the Company since the date hereof, nor an indication that BSL has performed any due diligence on the  Company or its affairs. This Presentation does not constitute an offer to sell or solicitation of an offer to buy securities in any jurisdiction where, or to any person to whom, it is unlawful to make such offer or solicitation in such jurisdiction.

This Presentation includes certain statements, estimates and projections with respect to the anticipated future performance of the Company. Such statements, estimates and projections are based on significant assumptions and subjective judgment concerning anticipated results. These assumptions and judgments are inherently subject to risks, variability and contingencies, many of which are beyond the Company’s control. These assumptions and judgments may or may not prove to be correct and there can be no assurance that any projected results are obtainable or will be realized. Actual results likely will vary from those projected, and such variations may be material. In addition, this Presentation does not describe certain risks associated with the Company’s business.

All communications or inquires relating to the Company or this Presentation should be directed to the representative of Boustead Securities LLC. No personnel at the Company may be contacted directly unless expressly permitted by Boustead Securities LLC. © 2020 Boustead Securities, LLC. All rights reserved.

Slide 9, Note 1:  Know Labs Management.

Slide 10, Note 1:  “Global Continuous Glucose Monitoring (CGM) Devices Market to Surpass US$ 18 Billion by 2025.” Globe Newswire News Room, Coherent Market Insights , 21 May 2018, https://globenewswire.com/news-release/2018/05/21/1509416/0/en/Global-Continuous-Glucose-Monitoring-CGM-Devices-Market-to-Surpass-US-18-Billion-by-2025.html.

Slide 10, Note 2:  “The CGM Market in Europe 2018-2024: Market Is Expected to Exceed $800 Million by the End of 2024 - ResearchAndMarkets.com.” AP News, Associated Press, 16 July 2018, www.apnews.com/0612facc940c4a1a9bbe7d525574ff33.

Slide 10, Note 5:  “North America Continuous Glucose Monitoring Market 2020-2025 – Modor Intelligence, 2019 https://www.mordorintelligence.com/industry-reports/north-america-continuous-glucose-monitoring-market.

Slide 11, Note 1:  “Global Continuous Glucose Monitoring (CGM) Devices Market to Surpass US$ 18 Billion by 2025.” Globe Newswire News Room, Coherent Market Insights , 21 May 2018, https://globenewswire.com/news-release/2018/05/21/1509416/0/en/Global-Continuous-Glucose-Monitoring-CGM-Devices-Market-to-Surpass-US-18-Billion-by-2025.html.

Slide11, Note 2:  “The CGM Market in Europe 2018-2024: Market Is Expected to Exceed $800 Million by the End of 2024 - ResearchAndMarkets.com.” AP News, Associated Press, 16 July 2018, www.apnews.com/0612facc940c4a1a9bbe7d525574ff33.

Slide 11, Note 3:  “Global Diabetes Market 2018 Share, Trend, Segmentation and Forecast to 2023.” MarketWatch, MarketWatch, 13 Aug. 2018, www.marketwatch.com/press-release/global-diabetes-market-2018-share-trend-segmentation-and-forecast-to-2023-2018-08-13.

Slide 11, Note 4:  “Diabetes.” World Health Organization, World Health Organization, 30 Oct. 2018, www.who.int/news-room/fact-sheets/detail/diabetes.

Slide 11, Note 5:  Ogurtsova, K., et al. “IDF Diabetes Atlas: Global Estimates for the Prevalence of Diabetes for 2015 and 2040.” Diabetes Research and Clinical Practice, vol. 128, 31  Mar. 2017, pp. 40–50., doi:10.1016/j.diabres.2017.03.024. https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(17)30375-3/pdf.

Slide 11, Note 6:  “Diabetes.” World Health Organization, World Health Organization, 30 Oct. 2018, www.who.int/news-room/fact-sheets/detail/diabetes.

Slide 12, Note 1:  “Global Diabetes Market 2018 Share, Trend, Segmentation and Forecast to 2023.” MarketWatch, MarketWatch, 13 Aug. 2018, www.marketwatch.com/press-release/global-diabetes-market-2018-share-trend-segmentation-and-forecast-to-2023-2018-08-13.

Slide 12, Note 2:  Senthilingam, Meera. “”40 Million people with diabetes will be left without Insulin by 2030.” 21 Nov. 2018, https://www.cnn.com/2018/11/21/health/global-insulin-shortage-diabetes-intl/index.html.

Slide 13, Note 1:  “Know Labs Announces Racer Technology as Manufacturing Partners.” Business Wire. 1 May 2019, https://finance.yahoo.com/news/know-labs-announces-racer-technology-130000674.html.

Slide 14/15, Note 1:  Know Labs Test Results.

Slide 17/18, Note 1:  Know Labs Business Plans, S-1/A filed November 14, 2019.

Slide 19, Note 1:  Know Labs Estimates.

Slide 20/21 Note 1:  Know Labs Test Results.